We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA is now prioritizing its review of Emergency Use Authorization (EUA) requests on a smaller subset of experienced developers applying for tests that are likely to have either a significant public health benefit or fulfill an unmet need, according to final guidance released by the agency Tuesday. Read More
Artivion’s study of its On-X mechanical aortic valve with the anti-clotting drug apixaban rather than warfarin was halted early for futility. Read More
Observations from the FDA’s Software Precertification Pilot Program confirmed that the rapidly evolving device software category needs a new “regulatory paradigm,” the agency said in a report on the now-completed pilot. Read More
The FDA has published draft guidance outlining an ethical framework for involving children in clinical trials of drugs and devices, as well as trial design considerations. Read More
Reauthorization of FDA’s user fee legislation moved ahead a step last week as leaders of the Senate Health, Education, Labor and Pensions (HELP) Committee and the House Energy and Commerce Committee agreed to include a slimmed-down version of user fee legislation and smaller policy riders on a short-term government funding bill, or continuing resolution (CR). Read More
The FDA needs to revise its Emergency Use Authorization (EUA) policies for tests of future infectious disease outbreaks, the HHS Office of Inspector General recommends in a new report. Read More
The EU’s surveillance system for legacy in vitro devices must remain in place during the transition to the new In Vitro Diagnostic Regulation (IVDR), according to the Medical Device Coordination Group (MDCG) of the European Medicines Agency. Read More
The FDA and the National Institutes of Health have teamed up to fund small businesses that create innovative medical device development tools (MDDT), such as biomarker tests, clinician- and patient-reported outcome measures, nonclinical assessment models and digital health technologies. Read More
The FDA will require electronic submission of 510(k) applications by Oct. 1, 2023, according to a final guidance that provides standards for using the agency’s electronic Submission Template and Resource (eSTAR) portal. Read More
Boston Scientific’s Sentinel cerebral protection system did not meet the primary endpoint in a large randomized trial since “the data demonstrated a non-significant trend towards a lower rate of stroke in patients treated with the Sentinel device,” the company said in a presentation at the Transcatheter Cardiovascular Therapeutics annual scientific symposium in Boston, Mass. Read More